Micromedic - Home page


		Home About us CellDetect^® BRONJ Test Investors Contact us

	Micromedic – a Unique Cluster of Cancer Diagnostic Solutions			News
	Micromedic Technologies Ltd. specializes in the development and commercialization of innovative *in vitro* cancer diagnostic products and solutions. Our portfolio includes state-of-the-art technologies involving gene expression, biomarker and histochemical assays for early cancer detection and personalized medicine. Micromedic offers proprietary diagnostic solutions for multiple cancer diagnostic applications, providing practical answers to real unmet needs. Micromedic is a public company traded on the Tel Aviv Stock Exchange (TASE: MCTC).			8-4-2018 Announcement of an annual general assembly of shareholders of Micromedic Technologies, May 23, 2018 at 10:00 28-2-2018 Israeli breakthrough in noninvasive prostate cancer test 22-2-2018 Micromedic announced successful results of a clinical study designed to detect prostate cancer 12-2-2018 Micromedic reports a successful clinical study of a new product for prostate cancer detection 28-8-2017 Invitation to general assembly meeting 27-7-2017 Micromedic Announces routine use of CellDetect in additional CLIA Laboratory in the US 28-6-2017 Micromedic announces distribution agreement in Germany 24-5-2017 Micromedic announces significant purchase order from China 6-4-2017 Announcement of the annual general assembly of shareholders of Micromedic Technologies 27-11-2016 An extraordinary assembly of Micromedic's shareholders is scheduled on January 3rd, 2017 at 4pm in the Company's offices in Kyriat Atidim 24-11-2016 Micromedic announces approval to conduct an extended clinical study with CellDetect on prostate cancer diagnosis 19-7-2016 Announcement of an extraordinary assembly of shareholders of Micromedic Technologies 10-1-2016 Micromedic Announces Receipt of Regulatory Approval to Commercialize CellDetect® Bladder Cancer Monitoring Kit in Israel 29-11-2015 Micromedic Announces Cooperation with Axella Research for Financing and Execution of Clinical and Regulatory Activities Required for FDA Approval of CellDetect® Bladder Cancer Monitoring 1-9-2015 Micromedic Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of BRONJ 30-6-2015 Micromedic Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer 2-2-2015 Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence 1-7-2014 Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study 27-5-2014 Micromedic identifies new genetic markers to predict risk of developing BRONJ 26-5-2016 Announcement of the annual general assembly of shareholders of Micromedic Technologies 3-2-2014 Micromedic reports success in clinical pilot of its Cervical Cancer diagnostic product in a central hospital in Beijing 8-7-2013 Zetiq has signed a memorandum of understanding for collaboration in India 25-12-2012 Successful interim results in a trial of a test for recurrence of bladder cancer cells in urine specimens 3-10-2012 Zetiq receives patent approval in Japan for its cell staining technology 20-11-2012 Marketing approval for Zetiq's CellDetect in China 15-4-2012 BioLight will invest 4 million NIS for additional 5% of Micromedic 27-3-2012 Micromedic signed an investment agreement with BioMarCare Technologies Inc. 25-9-2011 BioLight acquires 21% of Micromedic

© Micromedic Technologies Ltd.	site map \| contact

Site by Site2goal \| Design Studio Michal Lehavi